Apex Biotechnology Corp. (TPE:1733)
Taiwan
· Delayed Price · Currency is TWD 28.70
0.00 (0.00%)
Apr 29, 2026, 1:30 PM CST
Apex Biotechnology Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 162.89 | 128 | 115.78 | 181.79 | 202.22 | Upgrade
|
| Depreciation & Amortization | 59.83 | 63.41 | 74.19 | 92.71 | 94.32 | Upgrade
|
| Other Amortization | 1.09 | 1.4 | 1.52 | 1.39 | 1.35 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 17.78 | 6 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -14.98 | -4.23 | 3.96 | 29.48 | -31.7 | Upgrade
|
| Stock-Based Compensation | - | - | - | - | 1.59 | Upgrade
|
| Provision & Write-off of Bad Debts | 14.32 | 0.05 | 1.82 | - | -3.5 | Upgrade
|
| Other Operating Activities | -9.32 | -11.24 | 10.85 | -45.74 | 33.62 | Upgrade
|
| Change in Accounts Receivable | -88.39 | -58.6 | 188.87 | -1.38 | -160.77 | Upgrade
|
| Change in Inventory | 90.52 | 67.61 | -17.96 | -116.67 | -136.05 | Upgrade
|
| Change in Accounts Payable | -4.34 | 67.96 | -96.22 | -59.51 | 99.31 | Upgrade
|
| Change in Unearned Revenue | -51.05 | 51.68 | -22.45 | -64.02 | 50.45 | Upgrade
|
| Change in Other Net Operating Assets | -0.47 | 22.64 | -47.74 | 2.56 | 29.02 | Upgrade
|
| Operating Cash Flow | 160.12 | 328.67 | 230.39 | 26.62 | 179.87 | Upgrade
|
| Operating Cash Flow Growth | -51.28% | 42.66% | 765.61% | -85.20% | -35.90% | Upgrade
|
| Capital Expenditures | -15.26 | -28.24 | -21.91 | -36.58 | -26.59 | Upgrade
|
| Sale (Purchase) of Intangibles | -4 | -1.39 | -3.07 | -4.07 | -3.6 | Upgrade
|
| Investment in Securities | 9.8 | - | - | -0.7 | -2 | Upgrade
|
| Other Investing Activities | 3.92 | -5.96 | 2.48 | -0.01 | -2.83 | Upgrade
|
| Investing Cash Flow | -5.54 | -35.6 | -22.5 | -41.37 | -35.02 | Upgrade
|
| Short-Term Debt Issued | 18.27 | 29.45 | 281.16 | 964.61 | 1,690 | Upgrade
|
| Total Debt Issued | 18.27 | 29.45 | 281.16 | 964.61 | 1,690 | Upgrade
|
| Short-Term Debt Repaid | -18.27 | -59.45 | -301.16 | -1,065 | -1,540 | Upgrade
|
| Long-Term Debt Repaid | -8.72 | -8.7 | -8.2 | -7.68 | -404.2 | Upgrade
|
| Total Debt Repaid | -26.98 | -68.15 | -309.35 | -1,072 | -1,944 | Upgrade
|
| Net Debt Issued (Repaid) | -8.72 | -38.7 | -28.2 | -107.68 | -254.2 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 12.25 | Upgrade
|
| Common Dividends Paid | -119.94 | -109.95 | -139.93 | -129.94 | -109.32 | Upgrade
|
| Other Financing Activities | - | -0.03 | -0.02 | 0.01 | -0.01 | Upgrade
|
| Financing Cash Flow | -128.66 | -148.67 | -168.14 | -237.6 | -351.27 | Upgrade
|
| Foreign Exchange Rate Adjustments | 8.49 | 6.24 | 10.59 | 28.72 | -25.19 | Upgrade
|
| Net Cash Flow | 34.41 | 150.64 | 50.34 | -223.63 | -231.61 | Upgrade
|
| Free Cash Flow | 144.86 | 300.43 | 208.48 | -9.97 | 153.28 | Upgrade
|
| Free Cash Flow Growth | -51.78% | 44.10% | - | - | -34.87% | Upgrade
|
| Free Cash Flow Margin | 7.45% | 16.22% | 12.44% | -0.44% | 7.19% | Upgrade
|
| Free Cash Flow Per Share | 1.44 | 2.99 | 2.08 | -0.10 | 1.45 | Upgrade
|
| Cash Interest Paid | 3.39 | 3.64 | 4.39 | 5.4 | 4.7 | Upgrade
|
| Cash Income Tax Paid | 21.77 | 48.43 | 18.9 | 24.04 | 9.19 | Upgrade
|
| Levered Free Cash Flow | 98.15 | 254.23 | 164.39 | -78.18 | 55.06 | Upgrade
|
| Unlevered Free Cash Flow | 100.27 | 256.51 | 167.14 | -74.81 | 62.89 | Upgrade
|
| Change in Working Capital | -53.73 | 151.29 | 4.5 | -239.01 | -118.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.